Free tool
FAERS Monitor: Isopto Atropine
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208151 or its brand name (Isopto Atropine, Atropine Sulfate). Reports on generic versions are filed under their own applications.
Reports
2,595
Serious
2,182
84% of reports
Hospitalization
978
Death reported
414
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective315
- off label use214
- macular degeneration199
- nausea192
- pyrexia162
- diarrhoea150
- pain138
- malaise132
- headache129
- death124
- weight decreased120
- constipation117
- erythema109
- anaemia105
- vomiting105
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 55 |
| 2005 | 62 |
| 2006 | 50 |
| 2007 | 55 |
| 2008 | 73 |
| 2009 | 45 |
| 2010 | 75 |
| 2011 | 67 |
| 2012 | 71 |
| 2013 | 60 |
| 2014 | 68 |
| 2015 | 78 |
| 2016 | 117 |
| 2017 | 97 |
| 2018 | 125 |
| 2019 | 184 |
| 2020 | 164 |
| 2021 | 152 |
| 2022 | 230 |
| 2023 | 237 |
| 2024 | 236 |
| 2025 | 189 |
| 2026 | 104 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,564 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| macular degenerationSignal | 199 | 137.3 | 120.0 | 26,361 |
| anaemiaSignal | 105 | 4.5 | 3.7 | 281 |
| constipationSignal | 117 | 4.4 | 3.6 | 301 |
| erythemaSignal | 109 | 4.3 | 3.6 | 275 |
| pyrexiaSignal | 162 | 3.8 | 3.3 | 336 |
| weight decreasedSignal | 120 | 3.5 | 2.9 | 213 |
| malaiseSignal | 132 | 2.4 | 2.1 | 113 |
| off label use | 214 | 2.0 | 1.7 | 107 |
| nausea | 192 | 2.0 | 1.7 | 94 |
| drug ineffective | 315 | 1.9 | 1.7 | 151 |
| diarrhoea | 150 | 1.9 | 1.6 | 63 |
| pain | 138 | 1.8 | 1.5 | 52 |
| vomiting | 105 | 1.8 | 1.5 | 38 |
| headache | 129 | 1.7 | 1.4 | 35 |
| death | 124 | 1.2 | 1.0 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.